115 related articles for article (PubMed ID: 4039506)
1. [Use of monoclonal antibodies in the diagnosis of fibrinolysis].
Wojta J; Korninger C; Kirchheimer J; Hattey E; Turcu L; Binder BR
Wien Klin Wochenschr; 1985 Mar; 97(5):244-8. PubMed ID: 4039506
[TBL] [Abstract][Full Text] [Related]
2. Characterization of two monoclonal antibodies against human tissue-type plasminogen activator.
Schleef RR; Sinha M; Loskutoff DJ
Thromb Haemost; 1985 Apr; 53(2):170-5. PubMed ID: 4040658
[TBL] [Abstract][Full Text] [Related]
3. Production and characterization of monoclonal antibodies against tissue-type plasminogen activator.
Ding H; Wang JY; Song HY
Chin J Biotechnol; 1990; 6(3):223-7. PubMed ID: 2129498
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of epitopes on human tissue plasminogen activator recognised by a group of monoclonal antibodies.
MacGregor IR; Micklem LR; James K; Pepper DS
Thromb Haemost; 1985 Feb; 53(1):45-50. PubMed ID: 2581330
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function.
Wojta J; Binder BR; Huber K; Hoover RL
Thromb Haemost; 1989 Apr; 61(2):289-93. PubMed ID: 2501899
[TBL] [Abstract][Full Text] [Related]
6. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies.
Darras V; Thienpont M; Stump DC; Collen D
Thromb Haemost; 1986 Dec; 56(3):411-4. PubMed ID: 3105111
[TBL] [Abstract][Full Text] [Related]
7. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.
Nielsen LS; Grøndahl-Hansen J; Andreasen PA; Skriver L; Zeuthen J; Danø K
J Immunoassay; 1986; 7(3):209-28. PubMed ID: 3091639
[TBL] [Abstract][Full Text] [Related]
8. A fibrin specific monoclonal antibody which interferes with the fibrinolytic effect of tissue plasminogen activator.
Gargan PE; Ploplis VA; Scheu JD
Thromb Haemost; 1988 Jun; 59(3):426-31. PubMed ID: 3142080
[TBL] [Abstract][Full Text] [Related]
9. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice.
Declerck PJ; Verstreken M; Collen D
Thromb Haemost; 1995 Nov; 74(5):1305-9. PubMed ID: 8607114
[TBL] [Abstract][Full Text] [Related]
10. Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis.
Wankiewicz A; Iwan-Zietek I; Kotschy M; Gwieździński Z
Med Sci Monit; 2002 Mar; 8(3):CR189-92. PubMed ID: 11887034
[TBL] [Abstract][Full Text] [Related]
11. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin.
Reed GL; Matsueda GR; Haber E
Trans Assoc Am Physicians; 1988; 101():250-6. PubMed ID: 2480017
[No Abstract] [Full Text] [Related]
12. Relationship between circulating plasminogen activators and tumor development in mice.
Colombi M; Rebessi L; Boiocchi M; Barlati S
Cancer Res; 1986 Nov; 46(11):5748-53. PubMed ID: 3093069
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies against human high molecular weight urinary urokinase: application for affinity purification of urinary prourokinase.
Wojta J; Kirchheimer JC; Turcu L; Christ G; Binder BR
Thromb Haemost; 1986 Jun; 55(3):347-51. PubMed ID: 3092391
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.
Nielsen LS; Andreasen PA; Grøndahl-Hansen J; Huang JY; Kristensen P; Danø K
Thromb Haemost; 1986 Apr; 55(2):206-12. PubMed ID: 3520936
[TBL] [Abstract][Full Text] [Related]
15. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen LS; Dombernowsky P; Danø K
J Lab Clin Med; 1988 Jan; 111(1):42-51. PubMed ID: 3121772
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of fibrinolysis by bispecific monoclonal antibodies reactive to fibrin and plasminogen activators.
Kurokawa T; Iwasa S; Kakinuma A
Thromb Res Suppl; 1990; 10():83-9. PubMed ID: 2107601
[TBL] [Abstract][Full Text] [Related]
17. [Functional characterization of a monoclonal antibody which interferes with the binding of t-PA to fibrin].
Orbe J; Montes R; Chordá C; Páramo JA; Rocha E
Sangre (Barc); 1994 Aug; 39(4):261-6. PubMed ID: 7985055
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes.
Lijnen HR; Wagner EF; Collen D
Thromb Haemost; 1997 Feb; 77(2):362-7. PubMed ID: 9157597
[TBL] [Abstract][Full Text] [Related]
19. In vitro effects of urokinase--prevention by different inhibitors.
Oethinger MD; Seifried E
Thromb Haemost; 1990 Nov; 64(3):402-6. PubMed ID: 1710833
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
